These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27903663)

  • 41. Pulmonary Arterial Hypertension.
    Dodson MW; Brown LM; Elliott CG
    Heart Fail Clin; 2018 Jul; 14(3):255-269. PubMed ID: 29966625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-related pulmonary arterial hypertension: clinical presentation and management.
    Sitbon O
    AIDS; 2008 Sep; 22 Suppl 3():S55-62. PubMed ID: 18845923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary Arterial Hypertension: Combination Therapy in Practice.
    Burks M; Stickel S; Galiè N
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):249-257. PubMed ID: 29511993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Practical management of riociguat in patients with pulmonary arterial hypertension.
    Halank M; Tausche K; Grünig E; Ewert R; Preston IR
    Ther Adv Respir Dis; 2019; 13():1753466619868938. PubMed ID: 31438774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation.
    Ko T; Hatano M; Nitta D; Muraoka H; Minatsuki S; Imamura T; Inaba T; Maki H; Yao A; Kinugawa K; Komuro I
    Heart Vessels; 2016 Jul; 31(7):1206-8. PubMed ID: 26081027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
    Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
    Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
    Monaco TJ; Davila CD
    Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
    Pan J; Lei L; Zhao C
    Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulmonary arterial hypertension: the burden of disease and impact on quality of life.
    Delcroix M; Howard L
    Eur Respir Rev; 2015 Dec; 24(138):621-9. PubMed ID: 26621976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Sex in the Pathophysiology of Pulmonary Hypertension.
    Docherty CK; Harvey KY; Mair KM; Griffin S; Denver N; MacLean MR
    Adv Exp Med Biol; 2018; 1065():511-528. PubMed ID: 30051404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients.
    Giordano N; Montella A; Corallo C; Ruocco G; Chirico C; Palazzuoli A; Nuti R; Pecetti G
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S182-9. PubMed ID: 26339897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heartbeat: Biomarkers and pulmonary artery hypertension.
    Otto CM
    Heart; 2016 Mar; 102(5):333-4. PubMed ID: 26869632
    [No Abstract]   [Full Text] [Related]  

  • 57. Pulmonary arterial hypertension.
    Murali S
    Curr Opin Crit Care; 2006 Jun; 12(3):228-34. PubMed ID: 16672782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of pulmonary hypertension with left heart disease: a concise review.
    Desai A; Desouza SA
    Vasc Health Risk Manag; 2017; 13():415-420. PubMed ID: 29158679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
    Park MH
    Catheter Cardiovasc Interv; 2008 Feb; 71(2):205-13. PubMed ID: 18327839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.